C H Pothecary

13 Papers

2 Citations

C H Pothecary is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.

Author Tools

Create citation map

Create Author Profile

Analyze C H Pothecary's Top Papers

Chat about Author

Papers

•Journal Article•10.1038/s41586-023-06034-3

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Erola Pairo-Castineira, +2301 more

- 17 May 2023

- Visual education

TL;DR: In this article , a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data was conducted, finding 49 genomewide significant associations, of which 16 have not been reported previously.

...read moreread less

100

Journal Article•10.1016/s2213-8587(23)00253-x

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, +7600 more

- 01 Oct 2023

TL;DR: In adults hospitalised with COVID-19, empagliflozin was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death so is not indicated for the treatment of such patients unless there is an established indication due to a different condition such as diabetes.

...read moreread less

Journal Article•10.1016/s2352-4642(23)00316-4

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

Saul N. Faust, +7308 more

- 01 Jan 2024

- The Lancet Child & Adolescent Health

TL;DR: The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab or anakinra with usual care for those with inflammation refractory to initial treatment.

...read moreread less

Journal Article•10.1016/S2468-1253(22)00389-2

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, +686 more

- 01 Dec 2022

- The Lancet Gastroenterology & Hepatology

TL;DR: It is found that higher neutralising antibody titres in patients aged 5 years and older with a diagnosis of IBD and being treated with infliximab or vedolizumab for 6 weeks or longer were associated with a lower hazard risk, compared with patients who had a breakthrough infection.

...read moreread less

Journal Article•10.1016/j.lanepe.2023.100809

Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort

P. Kirwan, +260 more

- 14 Dec 2023

TL;DR: Despite rapid waning of protection, vaccine boosters remain an important tool in responding to the dynamic COVID-19 landscape; boosting population immunity in advance of periods of anticipated pressure, such as surging infection rates or emerging variants of concern.

...read moreread less